Literature DB >> 23193354

A Review of the 2010 WHO Adult Antiretroviral Therapy Guidelines: Implications and Realities of These Changes for Zambia.

Devang M Patel1, Crispin Moyo, Christopher M Bositis.   

Abstract

Entities:  

Year:  2010        PMID： 23193354      PMCID： PMC3506379     

Source DB:  PubMed          Journal:  Med J Zambia        ISSN： 0047-651X


× No keyword cloud information.
  29 in total

1.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

Review 2.  Tuberculosis as part of the natural history of HIV infection in developing countries.

Authors:  Gabriel Chamie; Annie Luetkemeyer; Edwin Charlebois; Diane V Havlir
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

3.  Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Authors:  Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

4.  Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis.

Authors:  Joshua T Schiffer; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2007-02-01       Impact factor: 3.731

Review 5.  Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

Authors:  David Nolan; Silvana Gaudieri; Simon Mallal
Journal:  J HIV Ther       Date:  2003-05

6.  Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Authors:  Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar
Journal:  N Engl J Med       Date:  2009-12-01       Impact factor: 91.245

7.  Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.

Authors:  Reto Nüesch; Jintanat Ananworanich; Preeyaporn Srasuebkul; Ploenchan Chetchotisakd; Wisit Prasithsirikul; Wirat Klinbuayam; Apicha Mahanontharit; Thidarat Jupimai; Kiat Ruxrungtham; Bernard Hirschel
Journal:  AIDS       Date:  2008-01-02       Impact factor: 4.177

8.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Authors:  Michael Saag; Rukmini Balu; Elizabeth Phillips; Philip Brachman; Claudia Martorell; William Burman; Britt Stancil; Michael Mosteller; Cindy Brothers; Paul Wannamaker; Arlene Hughes; Denise Sutherland-Phillips; Simon Mallal; Mark Shaefer
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

9.  Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa.

Authors:  Bertran Auvert; Sylvia Males; Adrian Puren; Dirk Taljaard; Michel Caraël; Brian Williams
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

10.  Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Authors:  Kimberly Y Smith; Parul Patel; Derek Fine; Nicholaos Bellos; Louis Sloan; Philip Lackey; Princy N Kumar; Denise H Sutherland-Phillips; Cindy Vavro; Linda Yau; Paul Wannamaker; Mark S Shaefer
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177
View more
  1 in total

1.  Gastroenterology training in a resource-limited setting: Zambia, Southern Africa.

Authors:  Akwi W Asombang; Eleanor Turner-Moss; Anil Seetharam; Paul Kelly
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.